Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Xiliarx er større end risiciene ved Xiliarx til behandling af type 2- diabetes mellitus, når det anvendes som oral tostofbehandling i kombination med metformin, et sulfonylurinstofeller et thiazolidindion stof.
The Committee for Medicinal Products for Human Use (CHMP) concluded that Xiliarx’ s benefits in the treatment of type 2 diabetes mellitus are greater than its risks when used as dual oral therapy in combination with metformin, a sulphonylurea or a thiazolidinedione.